Search This Blog

Tuesday, August 6, 2019

Xeris Pharmaceuticals EPS misses by $0.32, beats on revenue

Xeris Pharmaceuticals (NASDAQ:XERS): Q2 GAAP EPS of -$1.28 misses by $0.32.
Grant income of $0.31M (-62.2% Y/Y) beats by $0.26M.
Cash and investments of $124.5M.
Press Release
Posted by at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)